Moreover, geographic differences exist in adverse outcomes, with studies in Taiwan, Hong Kong, and the United States showing higher incidences of heart failure, hyperlipidemia, and renal failure with DPP-4 inhibitors compared to biguanides [28]. The gene discussed is DPP4; the disease is hyperlipidemia.